Genentech has received FDA approval of Vabysmo® for the treatment of macular edema due to retinal vein occlusion (RVO) beyond six months. RVO affects over a million Americans and often involves long-term intravitreal therapy to address the chronic nature of the disease.
“This label update reinforces our commitment to delivering consistent, long-term solutions for patients with vision impairment,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “With Vabysmo’s well-established efficacy, this label update should help minimize disruptive treatment switches in patients with RVO who are benefitting from Vabysmo.”
“The updated dosing for Vabysmo empowers retina specialists with the flexibility to tailor treatment plans to each patient’s unique journey with RVO,” said Veeral Sheth, M.D., Partner and Director of Clinical Research at University Retina and Macula Associates. “By aligning Vabysmo’s label with real-world clinical practice, we can now offer seamless, continuous care that helps support longer-term outcomes for patients living with RVO.”
For more information visit https://www.Vabysmo.com.